Schedule 13G ownership disclosure

Contineum Therapeutics Inc

Class A Common Stock, par value $0.001 per share · CUSIP: 21217B100

Event date: 2026-10-21

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Squadron Master Fund LP

    Shares: 1,700,000.00 · Class: 5.1%

  • Squadron Capital Management LLC

    Shares: 1,700,000.00 · Class: 5.1%

  • Matthew Sesterhenn

    Shares: 1,700,000.00 · Class: 5.1%

  • William Blank

    Shares: 1,700,000.00 · Class: 5.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002050709-26-000029
Form type
SCHEDULE 13G
Filer
Squadron Capital Management LLC
CIK
CIK 2050709
Filed
Oct 28, 2026
Reporting period
Oct 21, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub